To date, the most frequently identified causal genes of ARVC have been those encoding the major adhesive junction proteins between adjacent cells, namely cardiac desmosomes. These genes belong to three superfamilies: the desmosomal adhesion molecules, for example, desmoglein (DSG) and desmocollin; the plakin family (links the desmosomal plaque to the IF cytoskeleton and desmoplakin [DP] ); and the armadillo family (adaptor proteins that form links between the adhesion molecules and DP). Examples are plakophilin and plakoglobin. [11] [12] [13] [14] [15] [16] Whole-exome sequencing (WES), in which coding regions from total genomic DNA are enriched by exon capture and processed for next-generation sequencing, is able to provide the comprehensive information for coding exons of the whole genome and greatly facilitates diagnostics of genetic disorders. [17] In this study, we employed the technology of WES in a Chinese family with a high prevalence for ARVC and identified a rare pathogenic DSG2 mutation. Thus, a feature in the pathology and pathogenesis of ARVC might involve disturbed DSG function.
Methods

Subjects and DNA preparation
A three-generation Chinese pedigree in Zhejiang was investigated in this study [ Figure 1 ]. The proband and other members of this pedigree received examinations, and detailed clinical information was obtained from each subject, including physical examination; electrocardiograms, echocardiograms, and when appropriate, Holter monitoring; treadmill testing; and age of presentation. The New York Heart Association (NYHA) classification was performed at Zhongshan Hospital, Fudan University. Peripheral blood samples from all of the participants were taken, and the genomic DNA was extracted. All the experiments were done in agreement with the Helsinki Declaration. In accordance with the rules of the Ethics Committee of Zhongshan Hospital, Fudan University (B2016-016R), written informed consent was obtained from all participants.
Whole-exome sequencing and analysis
We sequenced whole exomes of peripheral blood DNA from the family members (II-2) using a 39 Mb charge-coupled device (CCD) capture probe and HiSeq 2500 Sequencing System (Illumina Inc., San Diego, CA, USA) in PE125 format. Mean coverage of captured regions was 88× per sample, with 97%-98% exons covered with at least 10× coverage, and an average of 92% vbase call quality of Q30 or greater. Raw sequence reads were mapped against human genome GRCh37 and analyzed using in-house pipeline Langya, which automatically performs BWA mapping and Freebayes variant calling, followed by filtering against in-house and public databases and genetic models (autosomal dominant) fitting. Additional automatic filtering was applied to rule out sequencing artifacts. Variants together with clinical diagnosis keywords were passed to a search engine based on Natural language processing (NLP) of scientific and clinical literature. Sanger sequencing was performed on DNA from probands for genotype confirmation and the family members for familial co-segregation analysis.
Results
Clinical data
The first identified proband was a 45-year-old man (II-2), syncope for 4 months, diagnosed with "dilated cardiomyopathy" for 10 years, heart failure (NYHA II) a feeling of palpitations, and weakness when walking fast. An N-terminal pro-B-type natriuretic peptide (287.8 pg/ml) was detected. Electrocardiogram showed frequent ventricular premature beats, nonsustained ventricular tachycardia, and second-degree atrioventricular block. Echocardiographic study revealed biventricular global dysfunction, left ventricular ejection fraction, 47%, hypokinesis of the inferior and posterior segments of the left ventricular, and hypokinetic right ventricle with a paper-thin RV-free wall. His chest radiography showed mild cardiac enlargement [ Figure 2] . Computed tomography coronary angiography shows no coronary artery stenosis. The patient was diagnosed with ARVC and underwent implantation of an implantable cardioverter defibrillator (ICD). The patient was treated with routine drugs for heart failure β-blocker, namely angiotensin-converting enzyme inhibitor, aldosterone antagonist, and diuretic. His younger brother (II-2, 34 years old), was stricken with sudden death during sleep.
Mutant gene detection
To identify the causative gene for this family, we employed the technology of WES and identified a rare pathogenic DSG2 mutation c. 1592T>G (p.Phe531Cys), which existed in the proband (II-2) as well as other family members (I-1, I-2, III-1, III-2, and III-3) but only those who carry the homozygotic pair (II-2) developed ARVC. The homozygous recessive mutation in exon 10 of DSG2 confirms the clinical diagnosis and contributes to the genetic counseling for families with ARVC, which matched the criteria of the potential disease-causing gene. Cosegregation of the mutations in this pedigree was further confirmed by Sanger sequencing [ Figure 3 ]. The mutation was located in a conserved region predicted to be deleterious [ Figure 4 ].
discussion
ARVC is an inherited cardiomyopathy characterized by progressive fibrofatty replacement of cardiac myocytes, and SCD is the first manifestation in about 25% of cases. [18] Effective management of ARVC involves early diagnosis, SCD risk stratification, the minimization of ventricular arrhythmias, and the slowing of disease progression. [19] In order to reach these goals, current reliable clinical strategies include exercise restriction, beta-blocker medications, antiarrhythmic medications, catheter ablation, and ICD implantation. Despite the lack of prospective randomized clinical studies, several investigations into large patient registries have indicated that ICD implantation, the most efficient safeguard against arrhythmic SCD, supports improved survival. [19, 20] In the present study, we identified a rare homozygous mutation c.1592T>G (p.Phe531Cys) of the DSG2 gene from a Chinese Han race ARVC family, co-segregation of which was subsequently confirmed by Sanger sequencing. This is the first report of that variant described in ARVC with a positive family history. We were strongly inclined to believe that the novel mutation in DSG2 might be the causal mutation in this family. More efforts should be performed to determine whether the variant also exists in other dilated cardiomyopathy (DCM) populations with larger number of patients.
ARVC is most often involved with mutations in genes encoding desmosomal proteins, and DSG2 gene mutations account for 10%-20% of such cases. [21] In humans, there are four isoforms of DSG. [22] First discovered in 2006, DSG2 gene mutations have been identified in more than 70 ARVC patients. [16] In our study, the proband (II-2) met with more than three major criteria for the modified task force criteria; thus, we had a definite diagnosis of ARVC. [23] Two other family members also carried the mutation but without any cardiac symptoms, suggesting that the mutation was homozygous recessive. Furthermore, genetic analysis detected an ARVC-associated gene mutation, c.1592T>G (p.Phe531Cys) in exon 10 of DSG2, in the proband.
Genetic testing is an accurate and valid measure and plays an important role in the diagnosis of ARVC patients. [24] In contrast, conventional Sanger sequencing is a cumbersome and expensive approach in which only a limited number of genes could be tested. Next-generation sequencing techniques are cost-effective and can produce large amounts of data in one reaction. [25, 26] Since an overwhelming majority of the causative mutations identified at present are located in the coding regions and most of the infrequent coding sequence mutants are predicted to be functionally detrimental, exome sequencing is a powerful technology for mutation screening. [27] Genetic tests have not been widely applied mainly because of the costs of laboratory examinations and restriction of detecting techniques. [24] Therefore, much attention should be paid to the great significance of genetic testing and analysis in the diagnosis of cardiomyopathy.
In this research, we reported a rare ARVC family with recessive heredity and detected a novel mutation of DSG2 c.1592T>G (p.Phe531Cys) as its genetic causal. In spite of the low penetrance of this disease, the affected individual may experience SCD as their initial manifestation, so pre-symptomatic diagnosis and lifestyle modifications are of great benefit for the patient. Our study improves the understanding of pathogenic mechanism in ARVC and contributes to proper genetic counseling for affected probands and at-risk family members.
Figure 4:
The amino acid sequences alignment of desmoglein-2 in different species. The box indicates the P531 residue is highly conserved during the evolution
